Search

Search results

1. Access delayed, transparency denied

     Yet another patient appears on Global TV News unable to get an expensive prescription drug reimbursed by the Ontario provincial government, and the Minister of Health and Long-Term Care responds that “the provinces and territories are working together ...

2. Potential Impact of Delayed Access to Five Oncology Drugs in Canada

   Main Conclusions Slow regulatory and reimbursement approvals in Canada are affecting cancer survival. More than 5,000 patients could have been negatively affected by delayed federal regulatory and provincial reimbursement approval for Avastin, Halaven, ...

3. Access to New Oncology Drugs in Canada Compared with the United States and Europe

   Cancer is the leading cause of premature death in Canada and the numbers of new cases of several major cancers have remained relatively stable. New, better treatments are needed as soon as they can be introduced. Using previously published information, ...